Literature DB >> 8682589

Prognostic and predictive value of tumour angiogenesis in ovarian carcinomas.

G Gasparini1, E Bonoldi, G Viale, P Verderio, P Boracchi, G A Panizzoni, U Radaelli, A Di Bacco, R B Guglielmi, P Bevilacqua.   

Abstract

Experimental studies suggest that angiogenesis plays an important role in the pathogenesis of ascites and progression of ovarian cancer. To evaluate the association of intratumoral microvessel density (IMD) with the conventional clinicopathologic features and to determine the capability of these factors in predicting responsiveness to platinum-based chemotherapy and overall survival (OS) we studied 112 ovarian carcinomas. IMD was determined using the anti-CD31 antibody and immunocytochemistry. In the entire series, we correlated IMD with the other features. In the subgroup of patients with FIGO stage III-IV (60 cases), we correlated the factors studied, determined prior of treatment, with response to therapy and prognosis. The median IMD value, in the "hot spot", in the entire series was of 48 microvessels/field. IMD values were significantly higher in mucinous carcinomas than in the other histologic types. In FIGO stage III-IV patients IMD, age and performance status (PS) were significantly associated with the probability of pathologic response to chemotherapy in univariate analysis. However, only IMD and PS retained significance in multivariate analysis. The overall capability of the 2 variables to predict response was high. In FIGO stage III-IV patients IMD, age, PS, the amount of post-operative residual disease (PORD), histologic type and response to chemotherapy were significant prognostic indicators of OS in univariate analysis. In multivariate analysis only histologic type, PORD and PS retained significance. The overall capability of these 3 variables to predict OS was satisfactory.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8682589     DOI: 10.1002/(SICI)1097-0215(19960621)69:3<205::AID-IJC10>3.0.CO;2-6

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  26 in total

1.  Risk factors for GI adverse events in a phase III randomized trial of bevacizumab in first-line therapy of advanced ovarian cancer: A Gynecologic Oncology Group Study.

Authors:  Robert A Burger; Mark F Brady; Michael A Bookman; Bradley J Monk; Joan L Walker; Howard D Homesley; Jeffrey Fowler; Benjamin E Greer; Matthew Boente; Gini F Fleming; Peter C Lim; Stephen C Rubin; Noriyuki Katsumata; Sharon X Liang
Journal:  J Clin Oncol       Date:  2014-03-17       Impact factor: 44.544

2.  Molecular determinants of ovarian cancer plasticity.

Authors:  A K Sood; E A Seftor; M S Fletcher; L M Gardner; P M Heidger; R E Buller; R E Seftor; M J Hendrix
Journal:  Am J Pathol       Date:  2001-04       Impact factor: 4.307

3.  Role of vascular endothelial growth factor inhibitors in the treatment of gynecologic malignancies.

Authors:  Robert A Burger
Journal:  J Gynecol Oncol       Date:  2010-03-31       Impact factor: 4.401

4.  Relevant molecular markers and targets.

Authors:  Kathleen M Darcy; Russel J Schilder
Journal:  Gynecol Oncol       Date:  2006-10-10       Impact factor: 5.482

Review 5.  Angiogenesis in epithelian ovarian cancer.

Authors:  E S Bamberger; C W Perrett
Journal:  Mol Pathol       Date:  2002-12

6.  Study on tumor angiogenesis in epithelial ovarian carcinoma.

Authors:  Z Wang; H Wang; M Lin
Journal:  J Tongji Med Univ       Date:  2000

7.  In vivo intratumor angiogenic treatment effects during taxane-based neoadjuvant chemotherapy of ovarian cancer.

Authors:  Martin Pölcher; Christian Rudlowski; Nicolaus Friedrichs; Marieke Mielich; Tobias Höller; Mathias Wolfgarten; Kirsten Kübler; Reinhard Büttner; Walther Kuhn; Michael Braun
Journal:  BMC Cancer       Date:  2010-04-13       Impact factor: 4.430

Review 8.  Risks and benefits with bevacizumab: evidence and clinical implications.

Authors:  Carla Kurkjian; Edward S Kim
Journal:  Ther Adv Drug Saf       Date:  2012-04

9.  Angiogenesis and vascular survival ability in ovarian adenocarcinomas.

Authors:  A Giatromanolaki; E Sivridis; P Tsikouras; I Manavis; G Maroulis; M I Koukourakis
Journal:  Virchows Arch       Date:  2004-09-09       Impact factor: 4.064

10.  A current review of targeted therapeutics for ovarian cancer.

Authors:  Susana M Campos; Sue Ghosh
Journal:  J Oncol       Date:  2010-01-03       Impact factor: 4.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.